The aim of this study was to evaluate the direct effect of propofol (di-isopropyl phenol) on the contractile properties of gravid human uterine muscle.
In obstetric anaesthesia, it is important to know the effects that anaesthetic agents have on the gravid uterus. Many commonly used anaesthetic agents have significant effects on uterine muscle tone, this being particularly true of the volatile anaesthetic agents enflurane, halothane, isoflurane and sevoflurane, which reduce uterine contractility in a dose-dependent manner [1] [2] [3] [4] [5] [6] [7] [8] .
Drugs that relax the uterus can be employed to produce therapeutic uterine relaxation. This may be indicated for obstructed labour, shoulder dystocia and retained placenta. While therapeutic relaxation of the uterus may be required for the safe delivery of the neonate, these drugs may also contribute to increased perioperative blood loss 9 .
While propofol has not been approved in Australia for use in obstetric anaesthesia, there are many reports in the literature describing the use of this drug in the pregnant patient [10] [11] [12] [13] . However, effects that propofol may have on uterine contractility have not been clearly described.
The aim of this study was to evaluate the direct effect of propofol on gravid human uterine muscle contractility.
MATERIALS AND METHODS
This study was approved by the regional ethics committee. After obtaining written informed consent, six myometrial samples were obtained from six different healthy, full term parturients undergoing elective caesarean section under epidural or spinal anaesthesia. The specimen was obtained after the neonate was delivered. The muscle strip was obtained from the upper edge of the uterine incision. The specimen was immediately placed in Krebs solution at 5°C and used within three hours.
Small longitudinal strips (1×2×12 mm) of muscle were prepared using a dissecting microscope. Two individual strips were prepared from each myometrial sample. This resulted in a total of 12 experimental strips. These strips were then suspended in a bath of Krebs solution bubbled with carbogen (5% carbon dioxide and 95% oxygen) and maintained at a temperature of 36.5°C.
Following preparation, all specimens developed spontaneous regular contractions after about one hour. The contractions developed at a rate of one contraction every six to 10 minutes. The force of contraction was recorded continuously using an isometric tension transducer (Grass Instruments) and analysed digitally with Powerlab/chart for Windows (AD Instruments) software package. Contractility was measured by calculating the area under the curve of the tension versus time curve. Developed tension was measured by calculating the difference in tension between the baseline measurement and the peak tension during a contraction.
Control contractions were obtained prior to each test concentration of propofol. It took up to 20 minutes to achieve consistent contractions after each solution change. Therefore a 20-minute equilibration time was allowed and control measurements were obtained before exposing the specimen to the different concentrations of propofol. Following the control measurements the Krebs solution was replaced by Krebs solution with propofol in the test concentration. A 20-minute equilibration time was once again allowed with propofol and the mean of three consecutive contractions was measured and compared to the mean of the three preceding control measurements. The propofol solution was then removed and replaced with fresh pre-warmed Krebs solution and control obtained prior to the next propofol solution. This was repeated prior to each propofol concentration tested. The order of testing of the different propofol concentrations was varied to reduce the potential effects of deterioration of the specimen over time. Six specimens were exposed to the different propofol concentrations.
The concentrations tested were 2 µg/ml, 5 µg/ml and 8 µg/ml. These concentrations were selected because they are similar to those found in plasma during target-controlled anaesthesia [14] [15] [16] . The specimens were also exposed to intralipid in concentrations equivalent to that found in an 8 µg/ml solution of propofol, in order to determine whether this additive alone influenced uterine contractility.
The results were analysed for statistical significance using analysis of variance and Newman-Keuls multiple-comparison test (Number Cruncher Statistical System, JL Hintze, Kaysville, Utah, USA). Results were expressed as mean ±95% confidence interval. The results were considered statistically significant when P <0.05.
RESULTS
Following preparation, the muscle strips all developed spontaneous contractions with a frequency of one contraction every six to 10 minutes. A typical recording during a control contraction and while exposed to propofol is shown in Figure 1 .
When the propofol solution was added, the contractility gradually decreased over the first 20 minutes and then stabilised at a reduced contractility -hence the 20-minute equilibration time after each solution change. Propofol caused a decrease in contractility (the area under the curve of a tension time/curve) in a dose-dependent manner (Figure 2) .
The decrease in contractility from 2 µg/ml of propofol (89±6.5% of control) was not statistically significant. The reduction in contractility was statistically significant above this concentration, with contractility being reduced to 53±4.3% of control with 5 µg/ml propofol, and 45±4.1% of control with the 8 µg/ml propofol.
There was no significant effect on contractility with intralipid.
The developed tension, defined as the difference in tension between the baseline measurement and the peak tension during a contraction, was decreased at all propofol concentrations tested, in a dosedependent manner. In the 2 µg/ml propofol solution the tension was reduced to 94% of control, in the 5 µg/ml solution to 77% of control and in the 8 µg/ml solution down to 68% of control. However, there was no significant reduction in the developed tension associated with the solution containing intralipid ( Table 1) 
DISCUSSION
There have been many reports of propofol being used in obstetric anaesthesia [10] [11] [12] [13] , but there are limited data on its effects on the uterus. Propofol has been used for induction at caesarean section [10] [11] [12] [13] and we have in our institution recently used propofol in TIVA for the EXIT procedure (Ex-Utero Intrapartum Treatment) 17 .
Shin et al investigated the effects of propofol on human pregnant uterine muscle 18 . They showed that propofol at concentrations greater than 10 µg/ml reduced the active tension by 45% compared to control value (P <0.02).
Our study was designed to address the shortcomings of that study, which did not adequately address the issue of contractility but rather investigated developed tension, which does not include a temporal component. The area under the curve takes into account both the tension developed and the time over which this tension was maintained, better reflecting contractility and allowing comparison with similar studies. In studies looking at the effects on contractility of inhalational anaesthetics, contractility has been calculated by measuring the area under the curve of a tension/time curve 1 .
Shin et al demonstrated a significant reduction in tension at 10 µg/ml of propofol, but our study demonstrates a decrease in developed tension with propofol at lower concentrations. The proportional decrease in contractility was even greater and statistically significant.
Another confounder in the study reported by Shin et al was that they did not precede each test solution with a control. We flushed the organ bath with fresh Krebs after each test solution and obtained control contractions before the next test solution so that the different concentrations of propofol could be compared with the control measurements immediately prior to exposure. This approach minimises the potential effects of deterioration of the specimen over time.
The mechanism by which propofol causes a reduction in uterine contractility remains unclear. Numerous studies have investigated the mechanism of action of propofol on vascular smooth muscle and it is thought that propofol may have calcium channel blocking effects 19, 20 . Other studies suggest that propofol works through release of nitric oxide from the endothelial cells 21 . Whether these same mechanisms play a role in uterine muscle is not known and therefore needs further investigation.
Propofol seems to cause a lesser reduction in uterine contractility than the volatile anaesthetics, because sevoflurane causes a decrease in contractility to 50% of control at 0.94 minimum alveolar concentration and at 3.5 minimum alveolar concentration it abolishes all uterine activity 7 .
There are shortcomings of our study. This is an in vitro study and we do not know what the effects of plasma binding will have on the effect on contractility in vivo. Propofol has high plasma protein binding (>95%) 22 so the free propofol concentration is much lower. Further clinical investigation may help to clarify this issue further, however the large number of variables and the difficulty of conducting such studies in pregnant women make such research extremely difficult.
In conclusion, propofol decreases isolated human uterine muscle contractility in a dose-dependent manner, and intralipid has no significant effect on uterine muscle contractility.
